Torsdag 30 Juli | 22:59:13 Europe / Stockholm
Est. tid*
2027-02-24 08:30 Bokslutskommuniké 2026
2026-11-02 12:00 Kvartalsrapport 2026-Q3
2026-08-26 N/A Extra Bolagsstämma 2026
2026-08-05 12:00 Kvartalsrapport 2026-Q2
2026-05-31 - Kvartalsrapport 2026-Q1
2026-05-27 - X-dag ordinarie utdelning MAGLE 0.00 SEK
2026-05-26 - Årsstämma
2026-03-27 - Bokslutskommuniké 2025
2025-11-14 - Kvartalsrapport 2025-Q3
2025-08-01 - Kvartalsrapport 2025-Q2
2025-05-27 - X-dag ordinarie utdelning MAGLE 0.00 SEK
2025-05-26 - Årsstämma
2025-05-22 - Kvartalsrapport 2025-Q1
2025-03-27 - Bokslutskommuniké 2024
2024-12-30 - Extra Bolagsstämma 2025
2024-10-24 - Kvartalsrapport 2024-Q3
2024-10-04 - Extra Bolagsstämma 2024
2024-07-18 - Kvartalsrapport 2024-Q2
2024-04-26 - X-dag ordinarie utdelning MAGLE 0.00 SEK
2024-04-25 - Årsstämma
2024-04-18 - Kvartalsrapport 2024-Q1
2024-02-16 - Bokslutskommuniké 2023
2023-10-25 - Kvartalsrapport 2023-Q3
2023-07-18 - Kvartalsrapport 2023-Q2
2023-04-27 - X-dag ordinarie utdelning MAGLE 0.00 SEK
2023-04-26 - Årsstämma
2023-02-16 - Bokslutskommuniké 2022
2022-11-09 - Kvartalsrapport 2022-Q3
2022-08-17 - Kvartalsrapport 2022-Q2
2022-05-19 - X-dag ordinarie utdelning MAGLE 0.00 SEK
2022-05-17 - Årsstämma
2022-05-05 - Kvartalsrapport 2022-Q1
2022-02-25 - Bokslutskommuniké 2021
2021-12-14 - Extra Bolagsstämma 2021
2021-11-16 - Kvartalsrapport 2021-Q3
2021-08-17 - Kvartalsrapport 2021-Q2
2021-05-14 - Kvartalsrapport 2021-Q1
2021-05-03 - X-dag ordinarie utdelning MAGLE 0.00 SEK
2021-04-18 - Årsstämma
2021-02-25 - Bokslutskommuniké 2020
2020-11-27 - Extra Bolagsstämma 2020
2020-11-05 - Kvartalsrapport 2020-Q3
2020-07-14 - Kvartalsrapport 2020-Q2
LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Magle Chemoswed bygger på strategiska förvärv som syftar till att driva tillväxt och diversifiera risker. Koncernen omfattar tre verksamhetsområden. Magle Chemoswed, en kontraktsutvecklings- och tillverkningsorganisation (CDMO). Magle PharmaCept, ett försäljnings- och marknadsföringsföretag för utveckling och direktförsäljning av koncernens medicintekniska produkter, och Magle Biopolymers A/S, en specialiserad tillverkningsorganisation för Dextran-teknologi.

Analysera bolaget i Börsdata!

All ägardata du vill ha finns i Holdings!

Magle Chemoswed Holding AB (publ) announces successful completion of the written procedure in relation to its senior secured bonds 2025/2028 and its senior secured bonds 2026/2028

2026-07-30 15:10:00

On 13 July 2026, Magle Chemoswed Holding AB (publ) (the “Company”) announced that it had initiated a written procedure in relation to its (i) senior secured bonds 2025/2028 with ISIN SE0025197403 (the “Initial Bonds”) and (ii) senior secured bonds 2026/2028 with ISIN SE0029503697 (the “Bonus Bonds” and together with the Initial Bonds, the “Existing Bonds”) (the “Written Procedure”), to request the holders of the Existing Bonds to vote in favour of certain waivers and requests in order to implement the New Structure (as defined in the notice of the Written Procedure) by way of consenting to the proposals set out in the notice of the Written Procedure. The full details of the proposals are set out in the notice of the Written Procedure.

A sufficient number of holders of Existing Bonds participated in the Written Procedure and the requisite majority voted in favour of the proposals. The Company is therefore pleased to announce the successful completion of the Written Procedure.

The Company will initiate the implementation of the contemplated amendments and waivers as set out in the notice of Written Procedure and will update the market with a time plan for the implementation steps once available. Any holder of Existing Bonds who, in accordance with the instructions set out in the notice of the Written Procedure, has subscribed for Super Senior Bonds (as defined in the notice of the Written Procedure) will be contacted directly.